Bluebird bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.445
- Today's High:
- $3.6
- Open Price:
- $3.58
- 52W Low:
- $2.78
- 52W High:
- $8.58
- Prev. Close:
- $3.56
- Volume:
- 3188612
Company Statistics
- Market Cap.:
- $394.79 million
- Book Value:
- 3.335
- Revenue TTM:
- $4.03 million
- Operating Margin TTM:
- -3802.85%
- Gross Profit TTM:
- $-247244000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -16.19%
- Return on Equity TTM:
- -39.87%
Company Profile
Bluebird bio Inc had its IPO on 2013-06-19 under the ticker symbol BLUE.
The company operates in the Healthcare sector and Biotechnology industry. Bluebird bio Inc has a staff strength of 323 employees.
Stock update
Shares of Bluebird bio Inc opened at $3.58 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.45 - $3.6, and closed at $3.48.
This is a -2.25% slip from the previous day's closing price.
A total volume of 3,188,612 shares were traded at the close of the day’s session.
In the last one week, shares of Bluebird bio Inc have slipped by -10.77%.
Bluebird bio Inc's Key Ratios
Bluebird bio Inc has a market cap of $394.79 million, indicating a price to book ratio of 4.3684 and a price to sales ratio of 125.4941.
In the last 12-months Bluebird bio Inc’s revenue was $4.03 million with a gross profit of $-247244000 and an EBITDA of $-148300000. The EBITDA ratio measures Bluebird bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bluebird bio Inc’s operating margin was -3802.85% while its return on assets stood at -16.19% with a return of equity of -39.87%.
In Q1, Bluebird bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 22.4%.
Bluebird bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0.32
Its diluted EPS in the last 12-months stands at $-1.67 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.32. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bluebird bio Inc’s profitability.
Bluebird bio Inc stock is trading at a EV to sales ratio of 161.9721 and a EV to EBITDA ratio of -1.9086. Its price to sales ratio in the trailing 12-months stood at 125.4941.
Bluebird bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $692.74 million
- Total Liabilities
- $115.93 million
- Operating Cash Flow
- $82.14 million
- Capital Expenditure
- $1.10 million
- Dividend Payout Ratio
- 0%
Bluebird bio Inc ended 2024 with $692.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $692.74 million while shareholder equity stood at $354.74 million.
Bluebird bio Inc ended 2024 with $0 in deferred long-term liabilities, $115.93 million in other current liabilities, 1064000.00 in common stock, $-3965263000.00 in retained earnings and $5.65 million in goodwill. Its cash balance stood at $239.05 million and cash and short-term investments were $318.26 million. The company’s total short-term debt was $51,404,000 while long-term debt stood at $0.
Bluebird bio Inc’s total current assets stands at $351.07 million while long-term investments were $0.00 and short-term investments were $79.21 million. Its net receivables were $15.54 million compared to accounts payable of $19.24 million and inventory worth $3.81 million.
In 2024, Bluebird bio Inc's operating cash flow was $82.14 million while its capital expenditure stood at $1.10 million.
Comparatively, Bluebird bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.48
- 52-Week High
- $8.58
- 52-Week Low
- $2.78
- Analyst Target Price
- $7
Bluebird bio Inc stock is currently trading at $3.48 per share. It touched a 52-week high of $8.58 and a 52-week low of $8.58. Analysts tracking the stock have a 12-month average target price of $7.
Its 50-day moving average was $3.6 and 200-day moving average was $4.79 The short ratio stood at 5.32 indicating a short percent outstanding of 0%.
Around 104% of the company’s stock are held by insiders while 7026.3% are held by institutions.
Frequently Asked Questions About Bluebird bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.